 Spanish pharmaceutical company Grifols said on Monday it agreed to buy plasma assets in North America from South Koreas Green Cross for 460 million. Grifols will buy a plasma fractionation plant in Canada and two purification facilities and 11 plasma collection centres in the United States, the company said in a statement. Grifols is one of the worlds top producers of treatments based on human plasma. 